This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Despite their exciting potential, the smooth operation of cell therapy development trials requires extraordinary orchestration, perfectly aligning the product and patient journeys. While clinicalsupply is essential to any successful trial, autologous cell therapy trials occupy the far end of the spectrum regarding risk tolerance.
Every major pharma company is now involved in CGT development which has resulted in the approval of 28 therapies by the FDA thereby making CGT no longer a niche category of therapies. Allogeneic therapies begin with healthy donor samples to develop the eventual therapeutic product which can be administered to multiple patients.
NUCLIDIUM has signed a strategic collaboration deal with PharmaLogic for the manufacturing and clinicalsupply of copper-based theranostics ⁶¹Cu in the US. ⁶¹Cu The deal is set to speed up the development of NUCLIDIUM’s theranostic pipeline. The deal is set to speed up the development of NUCLIDIUM’s theranostic pipeline.
When selecting a clinicalsupply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial.
The expansion forms part of Catalent’s ongoing global strategy to increase its ability to handle, store and manage advanced therapies for clinicalsupply, and follows investments at its facilities in Philadelphia, Singapore, and Shanghai, China, in specialized, ultra-low temperature storage capabilities. With sites in the U.S.,
Signant Health has partnered with the software company o connect its platforms for the management of clinicalsupply chain inventory, labels, and content.
Find out solutions to mitigate the impact from clinicalsupply chain risk and discover how to improve dynamic drug supply forecasting strategies. Join this webinar to learn how supply forecasting and interactive response technology can help biotech companies improve supply planning and distribution while reducing cost and risk.
Clovis Oncology and ITM Announce Lutetium-177 ClinicalSupply Agreement Clovis Oncology and ITM Announce Lutetium-177 ClinicalSupply Agreement ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinicaldevelopment of Clovis Oncology’s Targeted Radionuclide Therapy candidate FAP-2286 BOULDER, … Continue reading (..)
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials.
Modern software development concepts from ecommerce applications are helping eClinical applications meet the precise needs of each clinical trial. IRT solutions help clinical trial sponsors meet the complexities of patient randomization and clinicalsupply management. How is Modern Software Impacting IRT Platforms?
The company has developed three bisphosphonates, clodronate, alendronate and Nerixia (neridronate), for the treatment of bone pathologies such as osteoarthritis. The company developed and launched Binosto (alendronate sodium) as the first and only buffered solution for osteoporosis. Alkindi is one of EffRx’s three marketed drugs.
Under the deal, Rentschler Biopharma’s ATMP facility in Stevenage, UK, will undertake the bioprocess development of adeno-associated virus (AAV) material. The company is developing new and differentiated gene therapies for the treatment of serious, but common eye diseases.
The company has been ranked in the Business Expansion and Research and Development categories in the Pharmaceutical Technology Excellence Rankings. Initially centered on Librela®, this agreement paves the way for developing and manufacturing other molecules in the coming years. until 2026. until 2026.
The company anticipates safety and clinical activity findings from the trial’s safety lead-in segment in the second half of the year. Syros has a clinicalsupply agreement in place with Roche and is delivering SY-5609 for a combination dosing cohort in the latter company’s ongoing Phase I/Ib INTRINSIC trial. .
AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinicaldevelopment of ATX01. In parallel, AlgoTx firmed-up ATX01’s development pathway via a pre-IND consultation with the FDA and obtained an Orphan Drug Designation from the FDA to explore ATX01’s activity in erythromelalgia.
Contract development and manufacturing organization, Catalent, has invested in the capabilities at its clinicalsupply services facility in Philadelphia, in the US, to further support biotech firms developing cell and gene therapies.
Unlike commercial pharmaceutical packaging, the primary consideration in clinical trial packaging is protecting the product quality and reliability for research. Finding the best clinical trial packaging services providers.
Supply chain uncertainty is a challenge every clinicalsupply chain manager wrestles with – stemming from increasing product demand and quality, the growing complexity of clinical trial designs and a lack of visibility in the supply chain. Achieving clinicalsupply chain flexibility now and in the future.
Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinicalsupply and commercial launch. at the BioProcess International Theater.
Analyzing the benefits and challenges of implementing direct-to-patient services in the clinicalsupply chain to help meet patient requirements, improve supply chain efficiency and accelerate speed to market.
The benefits of developing a patient-centric clinicalsupply chain.
Add bookmark.
–(BUSINESS WIRE)–Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinicalsupply … Continue reading → Morgan Healthcare Conference Catalent, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference SOMERSET, N.J.–(BUSINESS
Collaboration provides clinical trial sponsors with access to the world’s most efficient clinicalsupply processes using a single contract. As a result, global clinicalsupply and operations teams can now single source their commercial drug requirements by utilizing two best-in-class solution providers.
.
UK-based Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics for next-generation CAR-T therapeutics. The agreement also puts in place a three year clinicalsupply agreement for the two companies.
As the clinical trials industry adapts to the rising demand, it must also tackle important challenges concerning the way advanced medicines like cell and gene therapies are handled. Cell and gene therapies are not your typical clinicalsupply chain. The requirements When handling personalised medicines, time is of the essence.
Molecular Partners, a global leader in the development of DARPin® therapeutics, will be responsible for the conduct of phase 1 & 2 trials that may lead to emergency use approval; Novartis will be responsible for further development, manufacturing, distribution and commercialization.
Sonna is currently the President at NuPulse Inc, an early stage medical device company responsible for developing the first minimally invasive, long-term, ambulatory counterpulsation device that works in sync with the heart. The post Heart Failure Clinical Trials with Sonna Patel-Raman appeared first on Clinical Trial Podcast & Blog.
According to Tufts Center for the Study of Drug Development (CSDD), in a typical Phase Ill clinical trial, 119 protocol deviations are implemented on average, involving approximately one-third of all patients participating in that trial. 1 Tufts Center for the Study of Drug Development (CSDD); Jan/Feb 2022 Impact Report.
billion on offer in milestones if the programmes meet development and commercial objectives. According to a statement from the two companies, Arcturus will contribute its STARR self-amplifying mRNA vaccine and LUNAR lipid nanoparticle delivery platform, which has already been deployed in the development of COVID-19 vaccine ARCT-154.
About MorphoSys
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for patients suffering from cancer and autoimmune diseases. In 2017, Tremfya (R) , developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc.,
His goal is to accelerate the development of new therapies by creating innovative solutions that connect and empower the clinical trial ecosystem. The post Clinical Trial Site Networks with Christian Burns appeared first on Clinical Trial Podcast & Blog. A native of Philadelphia, Christian holds a B.A.
Food and Drug Administration (FDA) has granted Fast Track designation to VTX-801, Vivet’s clinical-stage gene therapy for the treatment of Wilson Disease – a rare, genetic disorder that reduces the ability of the liver and other tissues to regulate copper levels, causing severe hepatic damage, neurological symptoms, and potentially death.
BioNTech plans to manufacture additional therapeutic and vaccine drug candidates at the plant, such as other mRNA vaccines, antibody and cell and gene therapy candidates to support the development of its diversified cancer and infectious disease product pipeline.
MP0420 is subject to an option and license agreement with Novartis AG to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program. Upon option exercise, Novartis would be responsible for all further development and commercialization activities. Chief Medical Officer of Molecular Partners.
This could be seen as a positive for companies developing CAR T-cell therapies for autoimmune diseases and solid tumors. According to Carvykti co-developer Legend Biotech, across US treatment centers that offer both therapies, Carvykti holds around 80 percent of the late-line market share.
Don’t involve RTSM too late If it’s beneficial to involve RTSM early , then conversely, it’s a bad thing to leave RTSM development until closer to FPI. Delaying RTSM development increases the risk of compromises, phased deliveries, or worst-case scenario, needing enhancements mid-study. That’s common sense.
Don’t involve RTSM too late If it’s beneficial to involve RTSM early , then conversely, it’s a bad thing to leave RTSM development until closer to FPI. Delaying RTSM development increases the risk of compromises, phased deliveries, or worst-case scenario, needing enhancements mid-study. That’s common sense.
Don’t involve RTSM too late If it’s beneficial to involve RTSM early , then conversely, it’s a bad thing to leave RTSM development until closer to FPI. Delaying RTSM development increases the risk of compromises, phased deliveries, or worst-case scenario, needing enhancements mid-study. That’s common sense.
Trial to be paused pending analysis of data and evaluation of plans for further development.
In addition, travel restrictions could create logistical challenges for the shipment of clinicalsupplies. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
Don’t involve RTSM too late If it’s beneficial to involve RTSM early , then conversely, it’s a bad thing to leave RTSM development until closer to FPI. Delaying RTSM development increases the risk of compromises, phased deliveries, or worst-case scenario, needing enhancements mid-study. That’s common sense.
This innovative platform aims to revolutionize the industry by seamlessly connecting providers, distributors and suppliers, providing unprecedented visibility into supply and demand information. Developed in collaboration with Palantir Technologies Inc.,
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content